Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuramis Deep is a monophasic, cross-linked hyaluronic acid-based dermal filler developed by the South Korean biopharmaceutical company Medytox Inc. It is manufactured using proprietary SHAPE (Stable Hyaluronic Acid and Purification Enhancement) technology, which involves a two-step cross-linking process and enhanced purification to ensure safety and long-lasting results. The product contains 20 mg/mL of non-animal-derived stabilized hyaluronic acid (NASHA) and is primarily indicated for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds and marionette lines, as well as for lip augmentation and facial volume restoration. Clinical studies have demonstrated its non-inferiority to established fillers like Restylane in terms of efficacy and safety. Some versions of the product are formulated with 0.3% lidocaine to minimize patient discomfort during the injection process.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neuramis Deep.